Why Is Bausch Health (TSX:BHC) Expanding Beyond the S&P/TSX?

Highlights

• Diversified operations span pharmaceuticals, eye health, and medical aesthetics.
• Salix and Solta businesses continue supporting operational growth.
• Global healthcare portfolio serves patients across multiple therapeutic categories.

Bausch Health strengthens pharmaceutical manufacturing, eye care products, medical technologies, and international healthcare operations while participating in the S&P/TSX Composite Index across markets globally.

S&P/TSX Composite Index features many of Canada's largest publicly traded companies across diverse industries, including healthcare. Bausch Health (TSX:BHC) operates in the pharmaceutical and healthcare sector through businesses focused on prescription medicines, eye health products, aesthetic medical technologies, and gastroenterology treatments. The company maintains manufacturing, research, commercial, and distribution operations across numerous international markets. As one of Canada's established Healthcare Stocks , business activities span pharmaceuticals, medical devices, consumer healthcare products, and specialized therapeutic solutions.

Diversified Healthcare Portfolio

The company manages several operating segments serving different areas of healthcare. Salix Pharmaceuticals develops and commercializes products primarily addressing gastrointestinal disorders, while Solta Medical provides energy-based aesthetic medical technologies used in dermatology and cosmetic procedures.

Eye health operations include surgical equipment, contact lenses, ophthalmic pharmaceuticals, and vision care products supplied through healthcare providers worldwide. Additional businesses manufacture prescription medicines covering dermatology, neurology, infectious diseases, and other therapeutic categories.

Diversification across multiple healthcare disciplines enables operations to serve hospitals, physicians, pharmacies, clinics, and specialized medical providers across domestic and international markets.

Pharmaceutical Operations

Prescription pharmaceuticals remain a significant component of business activities. Gastrointestinal treatments developed through the Salix business continue supporting patients with digestive health conditions requiring specialized therapies.

The company also markets products across dermatology, neurology, and other medical specialties. Research, manufacturing, regulatory compliance, quality assurance, and commercial distribution support pharmaceutical operations throughout the product lifecycle.

Advanced manufacturing facilities operate under pharmaceutical production standards designed to ensure product quality, consistency, and regulatory compliance across multiple jurisdictions.

Commercial organizations coordinate product availability through wholesalers, healthcare systems, pharmacies, and authorized medical providers serving patients worldwide.

Within the S&P/TSX Composite Index, Bausch Health remains one of Canada's diversified healthcare companies with operations extending well beyond the domestic pharmaceutical market.

Eye Health and Medical Devices

Eye health products form another major component of company operations through a broad portfolio supporting vision care and ophthalmology.

Products include intraocular lenses, surgical equipment, contact lenses, ophthalmic pharmaceuticals, lens care solutions, and over-the-counter eye care products. Healthcare professionals utilize these products across hospitals, surgical centers, and ophthalmology clinics.

The Solta Medical business develops aesthetic medical devices using advanced energy technologies for dermatological and cosmetic procedures. These systems support skin resurfacing, tissue remodeling, and other minimally invasive treatments performed by qualified medical professionals.

Medical technology development combines engineering, clinical evaluation, manufacturing, and regulatory processes before products reach healthcare providers in approved markets.

Technology and Digital Healthcare

Digital technologies increasingly support pharmaceutical commercialization, patient education, and operational efficiency throughout the healthcare industry.

The company has expanded utilization of digital tools supporting patient engagement, healthcare communication, and commercial operations across selected product categories. Artificial intelligence technologies contribute to data processing, healthcare communications, and workflow optimization within broader digital transformation initiatives.

Healthcare organizations continue incorporating digital technologies that improve operational efficiency while supporting communication among providers, patients, and commercial organizations.

Research and development activities also incorporate technological advances throughout clinical, manufacturing, and regulatory processes.

International Operations

Business activities extend across North America, Europe, Latin America, Asia-Pacific, and additional international regions. Global operations provide access to diverse healthcare markets while supporting product availability across multiple regulatory environments.

Manufacturing facilities, distribution centers, research activities, and commercial organizations operate within numerous countries serving healthcare professionals and patients.

International expansion remains supported by regulatory approvals, healthcare partnerships, product registrations, and established commercial infrastructure across multiple therapeutic categories.

Healthcare demand continues evolving as aging populations, expanding medical services, and technological developments influence pharmaceutical and medical device markets worldwide.

Toward the end of the discussion, the S&P/TSX Composite Index continues providing relevant context for Canada's major multinational healthcare companies. Bausch Health (TSX:BHC) continues advancing pharmaceutical manufacturing, medical technology, eye health products, and global healthcare distribution across an extensive international operating network.